Spring bank pharmaceuticals, inc. (SBPH)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Grant revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

352

457

717

976

946

0

0

0

Operating expenses:
Research and development

23,006

23,270

22,633

23,061

21,341

19,751

19,111

16,676

14,525

13,075

11,921

11,423

10,955

14,017

14,008

13,386

11,995

7,539

0

0

0

General and administrative

9,820

9,751

9,585

9,397

9,306

8,719

9,048

8,957

8,414

8,178

7,414

6,898

6,500

5,739

5,444

5,558

5,154

5,003

0

0

0

Total operating expenses

32,826

33,021

32,218

32,458

30,647

28,470

28,159

25,633

22,939

21,253

19,335

18,321

17,455

19,756

19,452

18,944

17,149

12,542

0

0

0

Loss from operations

-32,826

-33,021

-32,218

-32,458

-30,647

-28,470

-28,159

-25,633

-22,939

-21,253

-19,335

-18,321

-17,383

-19,404

-18,995

-18,227

-16,173

-11,596

0

0

0

Other income (expense):
Interest income

1,134

1,254

1,353

1,353

1,226

999

752

622

462

369

251

137

120

96

0

0

0

-

0

-

-

Interest expense

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liabilities

-5,630

-8,212

-8,841

-7,150

-6,236

-4,617

-8,516

-4,072

3,566

6,795

0

0

0

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Net loss

-27,080

-24,097

-22,087

-23,955

-23,185

-22,854

-18,891

-20,939

-26,043

-27,679

-28,616

-21,936

-17,348

-17,366

-18,913

-18,162

-16,124

-11,564

0

0

0

Unrealized gain/(loss) on marketable securities

-37

-230

-247

-249

0

-

0

0

-

-16

4

11

15

11

0

0

0

-

0

0

-

Comprehensive loss

-27,117

-24,327

-22,266

-24,128

-23,283

-22,836

-18,936

-20,980

-26,062

-27,695

-28,612

-21,925

-17,333

-17,355

-18,928

-18,172

-16,143

-11,582

0

0

0

Net loss per common share:
Basic

-

-

-0.42

-

-

-

-0.59

-

-

-

-0.85

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-0.42

-

-

-

-0.59

-

-

-

-0.85

-

-

-

-

-

-

-

-

-

-

Weighted-average number of shares outstanding:
Basic

-

-

16,459

-

-

-

14,841

-

-

-

12,696

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

16,459

-

-

-

14,841

-

-

-

12,696

-

-

-

-

-

-

-

-

-

-

Net loss per common share - basic and diluted

-0.49

-

-

-0.28

-0.32

-

-

-0.29

-0.37

-

-

-0.93

-0.69

-0.13

-0.53

-0.62

-1.11

-0.68

-0.59

-0.39

-0.37

Weighted-average number of shares outstanding - basic and diluted

16,523

-

-

16,443

16,436

-

-

13,179

12,991

-

-

9,517

9,416

8,465

7,759

6,923

5,877

5,802

5,796

5,796

5,336